Restanza for sale as ALS runs out of cash
This article was originally published in Scrip
Executive Summary
Advanced Life Sciences has failed to secure the finances required to complete the development of its antibiotic Restanza (cethromycin) and has decided to "evaluate strategic alternatives, including a possible sale of the company".